Related Experiment Video
Updated: Jan 11, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Sleep quality during preparation for RAI: recombinant TSH vs. levothyroxine withdrawal
Georgios K Markantes1, Konstantinos Dimitropoulos1, Anastasia Armeni1
1Division of Endocrinology - Department of Internal Medicine, University of Patras School of Health Sciences, Patras, Greece.
Background:
Patients with differentiated thyroid cancer (DTC) suffer from impaired sleep quality, which may be further impaired after radioactive iodine (RAI) treatment. The potential contribution of the type of preparation for RAI has not been studied. Our objective was to compare the effect of the types of preparation for RAI on the sleep quality of DTC patients, and to correlate sleep indices with hormonal and psychological parameters.
Methods:
we studied 104 DTC patients (76 women and 28 men) programmed to receive RAI, two to eight months after total thyroidectomy. Participants were classified into two groups, based on the type of preparation: 56 were prepared with levothyroxine withdrawal (LT4-W group) and 48 with recombinant human TSH (rhTSH) administration (rhTSH group). Assessment was done in the morning of RAI administration and included hormonal determinations (thyroid function tests, prolactin, cortisol, and adrenocorticotropic hormone) and evaluation of sleep quality (Pittsburg Sleep Quality Index-PSQI) and anxiety/depression levels (Hospital Anxiety and Depression Scale-HADS).
Results:
The two study groups did not differ in age and gender distribution, DTC histology, RAI indications and administered dose, thyroglobulin and anti-thyroglobulin antibodies levels. The rhTSH group demonstrated higher TSH and free thyroxine, and lower prolactin and cortisol; participants of this subgroup had better subjective quality (0.65 ± 0.71 vs 1.22 ± 0.92, p=0.002) and efficiency (0.35 ± 0.74 vs 0.72 ± 0.96, p=0.023), less daytime dysfunction (0.52 ± 0.59 vs 0.87 ± 0.82, p=0.03), and better global PSQI score (4.72 ± 3.32 vs 6.60 ± 3.99, p=0.014), while they also showed lower anxiety/depression scores compared to individuals in the LT4-W group (4.32 ± 4.22 vs 5.62 ± 3.85, p=0.046 and 3.55 ± 3.41 vs 5.86 ± 4.22, p=0.005, respectively). The between-groups differences in the above PSQI domains remained after correction for hormonal levels but disappeared (except for that in subjective quality) after correcting for anxiety/depression levels.
Conclusions:
In DTC patients receiving RAI, preparation with rhTSH could contribute to better sleep quality compared to LT4 withdrawal. Increased depression and anxiety rather than differences in hormone levels seemed to mediate this difference.
Related Concept Videos
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

